Panacea Biotec collaborates with Serum Institute of India

For manufacture and sale of fully liquid wP-IPV based Hexavalent Vaccine

Panacea Biotec has signed two long term agreements with Serum Institute of India (SII) and SII's wholly owned subsidiary, Bilthovan Biologicals B.V.

Under the collaboration, SII is entitled to manufacture and sell fully liquid whole cell pertussis (wP) and salk based injectable polio vaccine (IPV) based hexavalent vaccine developed and commercialised by Panacea Biotec, a first of its king in this category.

Under the collaboration, Serum Institute of India will ensure supply of IPV bulk to Panacea Biotech, an important constituent of the Hexavalent vaccine, from its wholly owned subsidiary BBIO, a bioengineering and pharmaceutical company, registered in the Netherlands having technology and expertise for making the IPV, earlier possessed by only 3 other vaccine manufacturers in the world.

Powered by Capital Market - Live News